Presentation Title: Neurofilament Light Chain in Neurodegenerative Diseases – Status Update
Session 2: Identification and Development of Novel Surrogate Endpoints for Use in Clinical Development Programs
Speaker: Terina Martinez, PhD
Summary:
Neurofilament Light Chain (NfL) has been used to study many neurodegenerative diseases including Multiple Sclerosis (MS), Alzheimer’s Disease, Parkinson’s Disease, and frontal temporal dementia. NfL has been an especially successful biomarker in clinical trials for progressive MS, demonstrating analytical and clinical validity. The Critical Path Institute is currently working to evaluate NfL as a surrogate biomarker across different neurodegenerative diseases.
Key Takeaways:
• NfL is a disease agnostic marker of axonal damage that can be measured in blood or cerebrospinal fluid that shows promise as a prognostic biomarker in several neurodegenerative diseases
• Understanding the biology of NfL release in healthy aging people as well as people with various neurodegenerative disorders would be beneficial to the advancement of this biomarker
• Use of a standardized assay for measuring NfL has advanced the use of NfL as a biomarker in MS
